Roger Moser
Lausanne, VD 1015, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Parkinson's disease-associated LRRK2 risk variant, G2385R, enhances Rab substrate phosphorylation and impairs neuronal integrity.
Journal: bioRxiv : the preprint server for biology
Published: May 07, 2026
Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTD.
Journal: Neurobiology of disease
Published: December 20, 2022
Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration.
Journal: Human molecular genetics
Published: April 18, 2014
HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation.
Journal: Brain : a journal of neurology
Published: January 25, 2014
Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily.
Journal: Human molecular genetics
Published: November 28, 2013
Comprehensive expression analyses of neural cell-type-specific miRNAs identify new determinants of the specification and maintenance of neuronal phenotypes.
Journal: The Journal of neuroscience : the official journal of the Society for Neuroscience
Published: March 22, 2013
MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition.
Journal: The Journal of neuroscience : the official journal of the Society for Neuroscience
Published: February 09, 2013
MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington's disease-related mechanisms.
Journal: PloS one
Published: July 17, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026